ストックスクリーナーアプリを入手
14.34
0.00%
0.010
前日終値:
$14.33
開ける：
$14.33
24時間の取引高:
988.85K
Relative Volume:
0.10
時価総額：
$4.50B
収益：
$571.16M
当期純損益:
$-38.10M
株価収益率:
-117.06
EPS:
-0.1225
ネットキャッシュフロー:
$-48.91M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.35%
6か月 パフォーマンス:
+79.35%
1年 パフォーマンス:
+56.61%
1日の値動き範囲:
$14.32
$14.34
1週間の範囲:
$14.32
$14.37
52週間の値動き範囲:
$5.51
$14.38
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.34 | 4.50B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.63 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.83 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-29 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-12-17 | 開始されました | Citigroup | Buy |
| 2025-09-18 | アップグレード | Needham | Hold → Buy |
| 2025-07-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - BioWorld MedTech
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock Price, Quote & Chart | AMICUS THERAPEUTICS INC (NASDAQ:FOLD) - ChartMill
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance - Markets Mojo
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio - simplywall.st
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 3 Month Share Price Rally - simplywall.st
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics: Q4 Earnings Snapshot - kare11.com
Amicus Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses - Intellectia AI
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives - Sahm
Will Amicus Therapeutics Inc. benefit from sector rotationEarnings Overview Report & Daily Entry Point Alerts - mfd.ru
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - The Manila Times
Decoding Amicus Therapeutics Inc (FOLD): A Strategic SWOT Insigh - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results - MarketBeat
Amicus Therapeutics (FOLD) Beats Q4 Revenue Expectations - GuruFocus
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
Is Amicus Therapeutics Inc.’s ROIC above industry averageWeekly Trading Summary & Intraday High Probability Setup Alerts - mfd.ru
TD Cowen cautious on Amicus Therapeutics (FOLD) despite positive 2025 revenue projections - MSN
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections - Finviz
Amicus earnings on deck as $4.8B BioMarin deal awaits vote - Investing.com India
Aug Levels: Will Amicus Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Principal Financial Group Inc. Has $2.08 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Current Valuations with Strong Revenue Growth - DirectorsTalk Interviews
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView
BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook - Yahoo Finance
Can Amicus Therapeutics Inc. expand its profit marginsPortfolio Gains Summary & Smart Swing Trading Techniques - mfd.ru
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):